Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

Brock Schroeder, PhD
Published: Tuesday, Dec 13, 2016



Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index (BCI) in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

In this study, researchers investigated 2 cohorts of patients who had ER-positive, early-stage disease with clinically low-risk breast cancer. Researchers sought to determine whether the BCI could stratify patients based on their risk of late recurrence. This is an important issue, Schroeder says, given the findings of the NSABP B-42 trial, which showed that only a small proportion of patients benefitted from extended endocrine therapy.

Results showed that even in the clinically low-risk patients, the BCI identified approximately 30% of those as being high risk for late recurrence. Those patients had a significantly elevated risk of recurrence compared with BCI low-risk patients. Although these are clinically low-risk tumors that are node-negative, they are likely to recurrence and benefit from extended endocrine therapy, he adds.
 
SELECTED
LANGUAGE


Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index (BCI) in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

In this study, researchers investigated 2 cohorts of patients who had ER-positive, early-stage disease with clinically low-risk breast cancer. Researchers sought to determine whether the BCI could stratify patients based on their risk of late recurrence. This is an important issue, Schroeder says, given the findings of the NSABP B-42 trial, which showed that only a small proportion of patients benefitted from extended endocrine therapy.

Results showed that even in the clinically low-risk patients, the BCI identified approximately 30% of those as being high risk for late recurrence. Those patients had a significantly elevated risk of recurrence compared with BCI low-risk patients. Although these are clinically low-risk tumors that are node-negative, they are likely to recurrence and benefit from extended endocrine therapy, he adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x